Page 9 - Recursion Operating System News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Recursion operating system. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Recursion Operating System Today - Breaking & Trending Today

Altitude Lab Launches Investor Coalition to Fund and Mentor Healthcare Startups in Utah


Zavain Dar, Lux Capital
Altitude Lab, a healthcare and life sciences incubator founded in 2020 by Recursion and The University of Utah s PIVOT Center, fills the critical role of attracting and supporting underrepresented entrepreneurs. The incubator focuses on developing diverse and inclusive businesses to innovate lower cost, higher quality, and more accessible healthcare solutions. Altitude Lab s first cohort includes nine minority or women founders, who are tackling everything from personalized chemotherapy strategies and cancer therapeutics to developing novel platforms to diagnose and triage liver disease.
Lack of access to top-tier investors is a crippling gap for founders in nontraditional geographies or of underrepresented backgrounds, explained Chandana Haque, executive director of Altitude Lab. Support from experienced investors can completely change the trajectory of a startup. It s our mission to connect founders from all backgrounds to the capital and resou ....

United States , University Of Utah , Katelin Roberts , Zachary Bogue , Jack Boren , Nickolas Mark , Nathaniel Horwitz , Alaa Halawa , Greg Yap , Chandana Haque , Jenna Barbari , Austin Walters , Zavain Dar , Michael Schmanske , Nan Li , Keith Marmer , Andrea Jackson , Recursion Charitable Foundation , Altitude Lab , University Of Utah Research Park , Members Of The Investor Coalition , Investor Coalition , Prnewswire Altitude Lab , University Of Utah Innovation Fund , Recursion Pharmaceuticals , Branden Rosenhan ,

Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis


Share this article
Share this article
SALT LAKE CITY, May 25, 2021 /PRNewswire/  Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company has initiated investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential prophylactic use in high-risk patients.
REC-163964 is the first internally-discovered New Chemical Entity (NCE) development candidate identified by the Recursion Operating System and advanced to IND-enabling studies. This lead represents one of three structurally-differentiated candidates discovered by Recursion s ML-enabled Operating System for the potential treatment of C. difficile. ....

Chris Gibson , Elyse Freeman , Exchange Commission , Recursion Pharmaceuticals Inc , Recursion Pharmaceuticals , New Chemical Entity , Recursion Operating System , Operating System , Recursion Map , Securities Litigation Reform Act , கிறிஸ் கிப்சன் , பரிமாற்றம் தரகு , புதியது இரசாயன நிறுவனம் , இயங்குகிறது அமைப்பு , பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் ,